3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
6
Neoplasms
5
Small Cell Lung Carcinoma
3
Neoplasm Metastasis
3
Nasopharyngeal Carcinoma
2
Esophageal Neoplasms
2
Colorectal Neoplasms
2
Breast Neoplasms
2
Advanced Cancer
2
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Stereotactic Body Radiation Therapy
1
Sarcoma
1
Recurrence
1
Platinum-resistant Recurrent Clear Cell Ovarian Cancer
1
Pheochromocytoma
1
Paraganglioma, Extra-Adrenal
1
Paraganglioma
1
Pancreatic Neoplasms
1
NSCLC
1
Lung Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Colonic Neoplasms
1
Carcinoma, Medullary
1
Brain Neoplasms
1
Advanced Solid Tumors
1
Advanced Malignancy
1
Advanced Endometrial Cancer
1
Adenocarcinoma of Lung
1
Interventions
anlotinib
1
Angiogenesis Inhibitors
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Stereotactic Body Radiation Therapy
×
anlotinib
×
Clear all
NCT04912128
2021-06-03
AnloSBRT
Peking University Third Hospital
Completed
30 enrolled